CHA sent a comment letter to the FDA on draft guidance that recommends how and when manufacturers provide additional information in drug shortage notifications to the agency. Our letter urges the FDA to address the specific challenges facing the pediatric drug supply chain through transparency requirements, developing proactive shortage mitigation plans, and ensuring an accounting of pediatric drugs on the FDA drug shortages list.
CHA Submits Comments on FDA Drug Shortage Guidance
Children’s Hospital Association sends a comment letter to the FDA on draft drug shortage guidance to highlight the need for an efficient pediatric supply chain.
Related Content
Pediatric Workforce Shortages Persist in 2024
Summary of Laboratory Developed Tests Final Rule
CHA Submits Energy and Commerce Committee Statement on Oversight of the 340B Drug Pricing Program
Pediatric Workforce Shortages Persist in 2024
Children’s hospitals continue to experience shortages across pediatric care fields with an outsized impact on mental and behavioral health specialties.
July 19, 2024
Summary of Laboratory Developed Tests Final Rule
Children's Hospital Association sent a letter to Energy and Commerce leaders supporting pediatric-focused legislation included in a recent markup.
July 17, 2024
CHA Submits Energy and Commerce Committee Statement on Oversight of the 340B Drug Pricing Program
Children's Hospital Association urges the committee to work with provider stakeholders to enhance the effectiveness and integrity of the program for children's health.
July 09, 2024
